315 results about "Propofol" patented technology

The present disclosure describes systems and methods of estimating sedation level of a patient using machine learning. For example, the integration of multiple QEEG features into a single sedation level estimation system using machine learning could result in a significant improvement in the predictability of the levels of sedation, independent of the sedative drug used. The present disclosure advantageously allows for the incorporation of large numbers of QEEG features and machine learning into the next-generation monitors of sedation level. Different QEEG features may be selected for different sedation drugs, such as propofol, sevoflurane and dexmedetomidine groups. The sedation level estimation system can maintain a high performance for detecting MOAA / S, independent of the drug used.

Buccal aerosol sprays using polar and / or non-polar solvents have now been developed which provide propofol for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: propofol, a polar solvent and an optional flavoring agent; formulation II: propofol, a polar solvent, a propellant, and an optionally flavoring agent; formulation III: propofol, a non-polar solvent, and an optional flavoring agent; formulation IV: propofol, a non-polar solvent, a propellant, and an optional flavoring agent; formulation V: propofol, a mixture of a polar solvent and a non-polar solvent, and an optional flavoring agent; and formulation VI: propofol, a mixture of a polar solvent and a non-polar solvent, a propellant, and an optional flavoring agent.

The invention includes compositions for transmucosal administration to an animal comprising at least one active agent and a pharmaceutically acceptable carrier. A preferred active agent is selected from the group consisting of meloxicam, carprofen, enrofloxacin, clemastine, diphenhydramine, digoxin, levothyroxine, cyclosporine, ondansetron, lysine, zolpidem, propofol, nitenpyram, ivermectin, milbemycin, and pharmaceutically acceptable salts, solvates and esters thereof. In another embodiment, the invention includes methods of treating or preventing a condition in an animal comprising transmucosally administering a composition comprising a therapeutically or prophylactically effective amount of an active agent and a pharmaceutically acceptable carrier.

The instant invention relates to a solid product comprising a liquid biologically active agent which is intimately associated to a stabilizing agent; particularly a solid product that can be reconstituted to a clear, stable, stabilized nanodispersion or loaded micelles comprising a polymer as a stabilizing agent and a liquid, preferably water immiscible, biologically active agent. The instant invention is further directed toward a process for the production of the above solid product; particularly to micelles or nanodispersions produced by hydration of a cake or powder of the solid product, produced via an effective treatment of a stabilized solution comprising for example a polymer as a stabilizing agent, such as an amphiphilic block copolymer or a small molecular weight surfactant, loaded with a liquid biologically active agent, such as propofol, an optional additive, and a suitable solvent.

The present invention provides a prodrug of propofol and crystalline forms thereof, methods of making the propofol prodrug and crystalline forms thereof, pharmaceutical compositions of the propofol prodrug and crystalline forms thereof, methods of using the propofol prodrug and crystalline forms thereof and pharmaceutical compositions thereof to treat diseases or disorders such as headache pain, post-chemotherapy or post-operative surgery nausea and vomiting, neurodegenerative disorders, and mood disorders.

The present invention provides propofol prodrugs, methods of making propofol prodrugs, pharmaceutical compositions of propofol prodrugs and methods of using propofol prodrugs and pharmaceutical compositions thereof to treat or prevent diseases or disorders such as migraine headache pain and post-chemotherapy or post-operative surgery nausea and vomiting.

The invention provides liquid compositions in the form of physically stable emulsions comprising a semifluorinated alkane. The semifluorinated alkane is comprised in the dispersed phase, which may also include an active pharmaceutical ingredient. One of the preferred active ingredients is propofol. The compositions are optionally heat sterilisable and can be used for pharmaceutical or cosmetic product applications, and administered topically, intravenously, or via other routes.

The present invention relates to aqueous pharmaceutical compositions comprising 2,6-diisopropylphenol (propofol). A composition of the present invention can comprise propofol and two or more excipients as an aqueous mixture. The propofol containing compositions are preferably sterile and are parenterally administered to any animal, including humans. The compositions are also chemically and physically stable over a wide range of environmental conditions.

The invention provides novel pharmaceutical compositions comprising the active ingredient propofol. Preferably, propofol is dissolved in at least one semifluorinated alkane. The compositions, which are preferably liquid or gel-like, may optionally comprise further excipients. They may be used as fill material in capsules, as buccal or nasal sprays, or as aerosols for pulmonary administration. They are particularly useful for the transmucosal administration of propofol.

The present invention provides aqueous pharmaceutical compositions containing a lipophilic therapeutic agent. In particular, the invention provides aqueous pharmaceutical compositions containing the compound 2,6-diisopropylphenol (propofol). Preferred compositions of the invention contain propofol in the presence of at least one block copolymer (for example, P188 or another poloxamer) and a polyethylene glycol (PEG). Compositions of the invention are preferably sterile or are readily sterilized (e.g., by autoclaving) and are suitable for parenteral administration to any animal, including humans. The compositions are also chemically and physically stable over a wide range of environmental conditions and for extended periods of time.

A rapid measuring system for the determination of the concentration of propofol in the respiratory flow, which can be designed in a compact form, has the features of a breathing gas line (1) including a breathing gas sensor (2) detecting the respiration, wherein the breathing gas sensor (2) is connected to an evaluating unit (3), a propofol sensor (5) with a downstream pump (6) is in gas flow connection with the breathing gas line (1), wherein the evaluating unit (3) is connected with the propofol sensor (5) and the pump (6), so that the evaluating unit (3) actuates the pump (6) for breathing gas sampling depending on the signal of the breathing gas sensor (2), and the propofol sensor (5) sends a measured signal for the concentration of propofol in the breathing gas to the evaluating unit (3).

A sterile pharmaceutical composition for parenteral administration of propofol, said composition comprising propofol, optionally albumin, and less than about 10% by weight solvent for propofol, wherein said composition is stored in a container having a closure wherein said closure is inert to propofol.

The invention relates to a phosphoryl carboxylic acid propofol ester derivative which has the general formula (I). The method comprises the following steps: propofol reacts with 2-halogenated carboxylic acid and a derivative thereof by alkali to obtain corresponding ester and then the product reacts with phosphoric acid or thiophosphoric acid and the derivative thereof by dissolvent to obtain a water-soluble product or the propofol reacts with a 2-halogenated carboxylic acid phosphate ester derivative by the alkali to obtain the corresponding ester and then the ester is catalyzed, hydrogenated and salified to obtain the water-soluble product (I). The preparation method has mild reaction condition, high yield, simple operation and industrialized prospect, and a prepared oral preparation has the characteristics of high bioavailability, rapid absorption, high stability, and the like; and auxiliary materials with safety defects, such as a surface active agent, and the like can not be added into the prepared injection, thereby improving the stability of the preparation, reducing or removing injection pain, increasing the compliance of patients, overcoming the defects of propofol emulsion and having the advantage of obvious effect. The invention has the structural general formula (I).

The invention discloses a rapid sensitive method for detecting a propofol anesthetic in blood. By adopting the ion-mobility spectrometry technology as a basic detection technology and adopting an anion mode, a rapid qualitative and quantitative analysis method for detecting the propofol anesthetic in the blood by ion-mobility spectrometry is established. The limit of detection can reach smaller than 1 ng (a concentration smaller than 0.1 ppm). The range of quantitative analysis concentrations is 0.5-20 ppm, thus meeting the human blood dose concentration analysis range. The analysis time of each sample is shorter than 30 s. No pretreatment technology is needed. The method is simple, rapid, efficient and high in reliability, and can be widely used for clinical-administration deep analysis and used for guiding the medication by a doctor.

The present invention provides propofol prodrugs, methods of making propofol prodrugs, pharmaceutical compositions of propofol prodrugs and methods of using propofol prodrugs and pharmaceutical compositions thereof to treat or prevent diseases or disorders such as migraine headache pain and post-chemotherapy or post-operative surgery nausea and vomiting.

The invention discloses a method for monitoring traced propofol narcotic rapidly and sensitively. In the method, an ion mobility spectrometry technology is taken as a basic detection technology, and an anion mode is adopted to establish a method for monitoring traced propofol narcotic. The method comprises the following steps: feeding a gas sample containing propofol into an ion mobility spectrometry tester for analysis to obtain a detecting signal, and then carrying out qualitation and quantitation. According to the invention, the measurement of a narcotic sample can be detected in real time, and the limit of detection of the propofol narcotic can reach 0.5ppb. The detecting method is simple, convenient, rapid and efficient and is good in reliability.

Irritation upon injection of a formulation containing propofol is reduced or substantially eliminated by administering a stable, sterile, and antimicrobial aqueous dispersion comprising a water-insoluble microdroplet matrix of mean diameter from about 50 nm to about 1000 nm consisting essentially of about 1% to about 15% of propofol, up to about 7% of a propofol-soluble diluent, and about 0.8% to about 4% of a surface stabilizing amphiphilic aent. The aqueous phase includes a pharmaceutically acceptable water-soluble polyhydroxy tonicity modifier. The propofol-containing dispersion is devoid of additional bactericidal or bacteriostatic preservative agents.

Methods of monitoring Propofol through a supply chain are disclosed herein. Consequently, the methods perform authentication of propofol as it is transported through the supply chain to the end user whereby propofol manufacturers and distributors can achieve data and product integrity and ultimately minimize cost.

The present invention relates to propofol derivatives comprising a cyclic or linear amino acid, or a poly- or (oligo)saccharide moiety, a process for preparing said derivatives, a method for anesthetizing a mammal as well as a method for treating convulsions, migraine or related diseases, or for the inhibition of free radicals in a mammal to which said compounds are administered. Furthermore, the present invention relates to said compounds for use as a medicament and the use of said compounds for the preparation of a medicament for anesthetizing a mammal or for treating convulsions, migraine or related diseases, or for inhibition of free radicals in a mammal.

The invention discloses a formula and preparation method of a novel propofol fat emulsion preparation which causes no pain or can be used for obviously lowering injection stimulation and pain. The novel preparation comprises the main constituents of propofol, an emulsifier, refined soybean oil or other refined oil as an oil-soluble diluent, oleic acid or oleate with the effect of assisting emulsification, vitamin E or derivatives thereof with an antioxidation effect, an ionic complexing agent, and glycerol or micro molecular sugar as an isoosmotic adjusting agent.

A formulation for anaesthetic use is described. The formulation contains propofol, and may be used to induce and / or maintain anaesthesia or sedation in a vertebrae. The formulation additionally contains a solvent or a combination of solvents and is suitable for mixing with commonly used infusion fluids prior to injection in to a patient. The formulation may be terminally sterilised using moist heat in order to assure sterility, and contains no lipid, thereby avoiding complications associated with administration over prolonged periods of time, or to patients with disorders of fat metabolism.

The present invention provides propofol prodrugs, methods of making propofol prodrugs, pharmaceutical compositions of propofol prodrugs and methods of using propofol prodrugs and pharmaceutical compositions thereof to treat or prevent diseases or disorders such as migraine headache pain and post-chemotherapy or post-operative surgery nausea and vomiting.

The invention discloses a propofol medium-long-chain fatty emulsion, which is made from the following components of: by weight, 10-20 parts of propofol, 50-100 parts of soybean oil, 50-100 parts of medium-chain triglyceride, 20-25 parts of glycerin, 6-12 parts of phosphatidylcholine bilayer, 0.02-0.05 part of sodium hydroxide, 0.3-0.6 part of oleic acid and injection water.

The present invention discloses an accurate quantitative analysis method for an ion mobility spectrum rapid detection sample. According to the method, based on the migration time obtained through qualitative analysis of an ion mobility spectrum, the thermal analysis process of the whole sample to be detected is completely recorded, and the recorded curve is defined as the tracking trend line of the thermal analysis of the sample; the samples with different concentrations are prepared by adopting the ion mobility spectrum technology as the base detection technology, and the tracking trend of the sample is subjected to data analysis; and by adopting the propofol in blood as an example, a standard curve equation y=671.48+934.42.x of the ion mobility spectrum detection is established between the plasma concentration of 1-20 ppm, wherein the correlation coefficient r is 0.9928. According to the present invention, the method is simple, rapid and efficient, and can be widely used for the quantitative analysis of the ion mobility spectrum rapid detection sample.

The invention provides a synthetic method for preparing a high-purity anesthetic, i.e., propofol (I). According to the method, the problem of difficulty in removing a large quantity of impurities with similar structures produced in the conventional preparation method is solved, and the emission of phenol pollutants is reduced.